Open Orphan #ORPH – Appointment of Group Chief Financial Officer
Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, is pleased to announce the appointment […]
Vox Markets Q&A with Open Orphan #ORPH Exec Chairman Cathal Friel
Open Orphan #ORPH Exec Chairman Cathal Friel discusses the completion of the hVIVO acquisition and provides an update on activities with Abraham Darwyne at Vox Markets.
Open Orphan #ORPH – Value the Markets Webinar
Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be hosting a webinar for investors at 7pm on Tuesday 11th February. For those wishing to […]
LSE interview – Cathal Friel refocuses Open Orphan #ORPH as he raises 5m and buys virology specialist hVIVO
In a wide-ranging interview with London South East, Open Orphan Executive Chairman Cathal Friel outlines his vision for the business and explains how the combined talents of Open Orphan, hVivo and Venn Life Sciences will create a soon to be profitable pharmaceutical services one-stop shop. Friel says this acquisition is the last however, as he […]
Open Orphan #ORPH presents at Shares Growth and Invention Forum, London
Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at the Shares Growth and Invention Forum on February 11, 2020 at Business Design […]
Open Orphan #ORPH – Upcoming Investor Events
Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 11th February […]
Proactive Investors interview with the Open Orphan #ORPH team on its future and ‘the lottery ticket’ sitting within hVIVO
Open Orphan PLC‘s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott following the completion last week of its £5.3mln fundraise. Also in studio is adviser to Open Orphan and founder of hVivo Professor John Oxford. Professor Oxford’s been a leader in the field of vaccine and anti-viral clinical trials for the last 20 years. […]
BRR Media – Open Orphan #ORPH business update
Cathal Friel, Executive Chairman of Open Orphan, provides an update on developments at the company following the successful fundraising, and also introduces Professor John Oxford – a leading expert in the field of virology and an original founder of hVIVO – who will be working with the company as a consultant.
Keeping pace with Open Orphan
It’s been an exceptionally busy few months for Open Orphan (ORPH) and its Executive Chairman Cathal Friel. Since reversing into Venn Life Sciences last summer, Open Orphan has set it’s sights on a series of acquisitions to forge a specialist pharmaceutical services group with a focus on orphan drugs. In raising the money to complete […]
Andrew Hore – Quoted Micro 3 February 2020
NEX EXCHANGE Zapp Electric Vehicles plans to join NEX in February. Zapp has developed an electric bike and it is being produced in Thailand. The first production series model was made in September. The flotation will raise cash for manufacturing and marketing the i300 in the European market where cities are promoting electric vehicles. Zapp […]